PMID- 36927932
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230404
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 64
IP  - 2
DP  - 2023 Mar 31
TI  - Clinical Outcomes of Cardiac Shockwave Therapy in Severe Coronary Artery Disease 
      Patients after Coronary Artery Bypass Grafting.
PG  - 137-144
LID - 10.1536/ihj.22-481 [doi]
AB  - Cardiac shockwave therapy (CSWT) is a noninvasive treatment for patients with 
      refractory angina or myocardial ischemia. This study aims to evaluate the 
      potential beneficial effect and safety of CSWT in patients with severe coronary 
      artery disease (CAD) who have undergone coronary artery bypass grafting 
      (CABG).This was a single-arm prospective cohort study. A total of 30 patients 
      with severe CAD who were not suitable for coronary revascularization and who had 
      undergone CABG were enrolled. All patients received CSWT for nine sessions. 
      Evaluation was performed before and after CSWT, including the Canadian 
      Cardiovascular Society (CCS) classification, New York Heart Association (NYHA) 
      classification, 6-minute walk test (6MWT), Seattle Angina Questionnaire (SAQ) 
      score, nitroglycerin dosage, echocardiography, myocardial perfusion imaging 
      (MPI), and safety parameters. All patients were followed up at both 1 month and 9 
      months after CSWT.After treatment, CSWT significantly improved CCS classification 
      (P < 0.05), NYHA classification (P < 0.05), nitroglycerin dosage (P < 0.001), and 
      6MWT (P < 0.05) at 1 month and 9 months after CSWT. SAQ score (P < 0.05) and left 
      ventricular ejection fraction (LVEF; P = 0.037) by echocardiography significantly 
      improved at 1 month after CSWT. Significant decreases in summed stress score 
      (SSS), summed difference score (SDS), ischemic area stress, and ischemic area 
      difference by MPI were observed at 1 month and 9 months after CSWT (P < 0.01). 
      There were no changes in safety parameters before and after CSWT.CSWT may have a 
      beneficial effect on improving myocardial perfusion, clinical symptoms, 
      exertional capacity, and quality of life and is a safe alternative treatment for 
      patients with severe CAD who have undergone CABG.
FAU - Wang, Jiannan
AU  - Wang J
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
AD  - Graduate School of Peking Union Medical College.
FAU - Jia, Na
AU  - Jia N
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Liu, Baoyi
AU  - Liu B
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Zhang, Ruisheng
AU  - Zhang R
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Liu, Bing
AU  - Liu B
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Lan, Ming
AU  - Lan M
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Liu, Junmeng
AU  - Liu J
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - Yao, Zhiming
AU  - Yao Z
AD  - Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
FAU - He, Qing
AU  - He Q
AD  - Department of Cardiology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences.
AD  - Graduate School of Peking Union Medical College.
LA  - eng
PT  - Journal Article
DEP - 20230315
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - G59M7S0WS3 (Nitroglycerin)
SB  - IM
MH  - Humans
MH  - *Coronary Artery Disease/surgery/diagnosis
MH  - Nitroglycerin
MH  - *High-Energy Shock Waves/therapeutic use
MH  - Stroke Volume
MH  - Prospective Studies
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Ventricular Function, Left
MH  - Canada
MH  - Coronary Artery Bypass
OTO - NOTNLM
OT  - Myocardial ischemia
OT  - Myocardial perfusion imaging
OT  - Novel noninvasive treatment
OT  - Refractory angina
EDAT- 2023/03/18 06:00
MHDA- 2023/04/04 06:42
CRDT- 2023/03/17 08:45
PHST- 2023/04/04 06:42 [medline]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/17 08:45 [entrez]
AID - 10.1536/ihj.22-481 [doi]
PST - ppublish
SO  - Int Heart J. 2023 Mar 31;64(2):137-144. doi: 10.1536/ihj.22-481. Epub 2023 Mar 
      15.